I was interested to read the paper by Grkovski M and colleagues published in the Dec 2016 issue of EJNMMI Res \[[@CR1]\]. They aimed to assess the reproducibility of 18F-fluoromisonidazole (FMISO) positron emission tomography (PET) as a non-invasive, quantitative imaging technique, spatiotemporal intratumour distribution in patients with non-small cell lung cancer (NSCLC) \[[@CR1]\]. The Pearson correlation coefficient *r* was calculated for mean standardized uptake values (SUV) within investigated volumes of interest and for voxels within tumour volumes (*r* ~TV~). The reproducibility of FMISO voxelwise distribution, SUV- and tumour-to-blood ratio (TBR)-derived indices was assessed using correlation and Bland-Altman analyses \[[@CR1]\]. Although they correctly used Bland-Altman, they reported Pearson's correlation *r* which in reproducibility (precision, repeatability, reliability, or interchangeability) is one of the common mistakes \[[@CR2]--[@CR6]\]. Pearson's correlation *r* only assesses the linearity between two continuous variables. Any shift in the location and/or scale of the regression line which leads to non-reproducibility cannot be detected by this correlation coefficient \[[@CR2]--[@CR6]\]. Therefore, for quantitative variables, Intra Class Correlation Coefficient single measure is the best statistical test to evaluate reproducibility \[[@CR2]--[@CR6]\].

Based on their results, the SUV~max~, SUV~mean~, TBR~max~, and TBR~mean~ were highly correlated (*r* ≥ 0.87, *p* \< 0.001) and were reproducible to within 10--15% \[[@CR1]\]. It is good to know that in reliability analysis, individual based approach should be considered instead of global average which Pearson's correlation *r* cannot do. It means we can simply get strongly positive and significant Pearson *r* (*r* = 0.95, *p* value \< 0.001) with no reproducibility at all. Moreover, statistically significant should not be considered in reproducibility analysis \[[@CR2]--[@CR6]\]. They concluded high reproducibility of FMISO intratumour distribution in NSCLC patients, facilitating its use in determining the topology of the hypoxic tumour sub-volumes for dose escalation, in patient stratification strategies for hypoxia-targeted therapies, and in monitoring response to therapeutic interventions. Such conclusion may be a misleading message due to inappropriate use of statistical test to assess reproducibility. Briefly, for reliability analysis, appropriate tests should be applied; otherwise, misdiagnosis and mismanagement of the patients cannot be avoided.
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